Sinda M Mein, MD
Gastroenterology · Menlo Park
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 9
- 1 carrier
- Office
- 1
Offices
1 location · University Healthcare Alliance · 334 clinicians in this group
Hospitals listed: Stanford Health Care. That is not proof they admit you there this week.
Plans that list them
9 plans · 1 carrier
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Mein’s office at (650) 498-6500 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
California Medical Board record
Licence A69657 · Current
Licensed to practise in California · since 1999 · expires 2026-11-30 · University of Southern California Keck School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Surgery centers they own
- Waverley Surgery Center, LPAmbulatory Surgery Center · Palo Alto, CA4.13% owner since 2018 · accredited by AAAHCAccreditation Renewed4 inspections, 3 with deficiencies · last 2024-04-25
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$78,565
Medicare paid this office $78,565 for 288 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Return visit (30+ min) | 153 | $24,655 | $111 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 82 | $19,312 | $236 |
| Biopsy of large bowel using a flexible endoscope | 119 | $11,238 | $94 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 80 | $7,539 | $91 |
| New patient visit (45+ min) | 52 | $7,423 | $143 |
See all 7 services
| Return visit (30+ min) | 153 | $24,655 | $111 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 82 | $19,312 | $236 |
| Biopsy of large bowel using a flexible endoscope | 119 | $11,238 | $94 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 80 | $7,539 | $91 |
| New patient visit (45+ min) | 52 | $7,423 | $143 |
| Long return visit (40+ min) | 22 | $4,097 | $164 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 68 | $1,094 | $14 |
Procedures Medicare counted
| Colonoscopy | 39 | More than 59% of doctors who do this |
| Upper gastrointestinal (GI) endoscopy for acid reflux | 38 | More than 59% of doctors who do this |
Who their Medicare patients are
288 Original Medicare patients in 2024. Average age 76 · Women 75% · Also on Medicaid 4% · Health risk score 0.95. At or below the middle of the specialty; the typical gastroenterology clinician is at 1.42.
Conditions among them: High blood pressure 58% · Coronary heart disease 24% · Diabetes 17% · Cancer 17% · Depression 17% · Chronic kidney disease 13% · Atrial fibrillation 13% · COPD 8% · Heart failure 6% · Stroke 6%.
The office billed $811,556, Medicare allowed $101,631 and paid $78,565; for 697 services of 25 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 288 | 697 | 76 | 0.95 | $811,556 | $78,565 |
| 2023 | 264 | 552 | 75 | 0.96 | $693,962 | $67,542 |
| 2022 | 273 | 539 | 75 | 0.90 | $682,530 | $63,686 |
| 2021 | 265 | 565 | 74 | 0.93 | $655,826 | $71,566 |
| 2020 | 200 | 383 | 75 | 1.10 | $399,222 | $43,132 |
| 2019 | 219 | 479 | 75 | 1.06 | $511,756 | $55,618 |
| 2018 | 253 | 765 | 74 | 0.92 | $536,521 | $61,268 |
| 2017 | 348 | 1,041 | 75 | 1.00 | $704,207 | $78,806 |
| 2016 | 347 | 668 | 73 | 0.90 | $649,344 | $79,741 |
| 2015 | 309 | 641 | 73 | 0.85 | $641,492 | $87,789 |
| 2014 | 279 | 536 | 73 | 0.97 | $507,788 | $65,752 |
| 2013 | 212 | 453 | 72 | 1.16 | $381,493 | $51,997 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 7 services
| Return visit (30+ min) | 127 | $19,684 | $110 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 74 | $16,341 | $221 |
| Biopsy of large bowel using a flexible endoscope | 103 | $7,865 | $76 |
| New patient visit (45+ min) | 45 | $6,081 | $135 |
| Long return visit (40+ min) | 31 | $5,259 | $164 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 58 | $4,897 | $82 |
| Diagnostic exam of anus with magnification and chemical agent enhancement using an endoscope | 15 | $2,094 | $131 |
2022: 7 services
| Return visit (30+ min) | 125 | $16,982 | $105 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 78 | $16,448 | $211 |
| Biopsy of large bowel using a flexible endoscope | 119 | $8,689 | $73 |
| New patient visit (45+ min) | 50 | $6,823 | $136 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 57 | $5,028 | $88 |
| Long return visit (40+ min) | 21 | $3,623 | $151 |
| Diagnostic exam of anus with magnification and chemical agent enhancement using an endoscope | 12 | $1,617 | $124 |
2021: 8 services
| Return visit (30+ min) | 138 | $24,079 | $122 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 62 | $13,548 | $219 |
| Biopsy of large bowel using a flexible endoscope | 112 | $11,182 | $100 |
| New patient visit (45+ min) | 52 | $7,346 | $141 |
| Long return visit (40+ min) | 24 | $4,896 | $175 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 56 | $4,469 | $77 |
| Diagnostic exam of anus with magnification and chemical agent enhancement using an endoscope | 12 | $1,670 | $139 |
| Short return visit (20+ min) | 12 | $752 | $63 |
2020: 8 services
| Return visit (30+ min) | 98 | $12,438 | $96 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 29 | $6,494 | $224 |
| Biopsy of large bowel using a flexible endoscope | 56 | $6,352 | $113 |
| Long return visit (40+ min) | 26 | $4,274 | $138 |
| New patient visit (45+ min) | 30 | $4,181 | $139 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 40 | $4,071 | $99 |
| Telephone medical discussion with physician, 21-30 minutes | 12 | $1,360 | $105 |
| Short return visit (20+ min) | 18 | $1,235 | $69 |
2019: 8 services
| Return visit (30+ min) | 116 | $16,531 | $101 |
| Biopsy of large bowel using a flexible endoscope | 80 | $9,557 | $118 |
| New patient visit (45+ min) | 62 | $9,035 | $146 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 33 | $7,612 | $224 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 49 | $4,553 | $91 |
| Long return visit (40+ min) | 16 | $2,883 | $137 |
| Short return visit (20+ min) | 27 | $1,985 | $71 |
| Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monito | 14 | $68 | $5 |
2018: 9 services
| Return visit (30+ min) | 108 | $13,629 | $93 |
| Biopsy of large bowel using a flexible endoscope | 106 | $12,136 | $114 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 51 | $11,557 | $227 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 65 | $6,046 | $90 |
| New patient visit (45+ min) | 33 | $4,925 | $149 |
| Long return visit (40+ min) | 19 | $2,355 | $124 |
| Short return visit (20+ min) | 22 | $1,338 | $56 |
| Use of a drug to induce depression of consciousness by physician performing a procedure, each additional 15 minutes | 83 | $1,296 | $11 |
| Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monito | 144 | $700 | $5 |
2017: 12 services
| Biopsy of large bowel using a flexible endoscope | 146 | $17,118 | $117 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 67 | $15,909 | $234 |
| Return visit (30+ min) | 116 | $14,132 | $95 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 73 | $7,095 | $89 |
| New patient visit (45+ min) | 42 | $6,187 | $147 |
| Use of a drug to induce depression of consciousness by physician performing a procedure, each additional 15 minutes | 140 | $2,099 | $11 |
| Long return visit (40+ min) | 14 | $1,902 | $119 |
| Short return visit (20+ min) | 31 | $1,804 | $58 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 17 | $1,490 | $88 |
| Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monito | 172 | $806 | $4 |
| Injection beneath lining of large bowel using a flexible endoscope | 15 | $399 | $27 |
| Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | 28 | $295 | $11 |
2016: 9 services
| Biopsy of large bowel using a flexible endoscope | 147 | $17,046 | $116 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 73 | $16,870 | $231 |
| Return visit (30+ min) | 105 | $14,090 | $95 |
| New patient visit (45+ min) | 52 | $7,048 | $136 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 61 | $5,141 | $83 |
| Short return visit (20+ min) | 46 | $3,585 | $62 |
| Long return visit (40+ min) | 15 | $2,016 | $126 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 13 | $1,160 | $89 |
| Injection beneath lining of large bowel using a flexible endoscope | 13 | $377 | $29 |
2015: 8 services
| Biopsy of large bowel using a flexible endoscope | 151 | $23,018 | $150 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 76 | $22,042 | $286 |
| Return visit (30+ min) | 96 | $12,803 | $101 |
| New patient visit (45+ min) | 53 | $7,720 | $146 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 62 | $5,350 | $85 |
| Short return visit (20+ min) | 48 | $3,735 | $68 |
| Long return visit (40+ min) | 14 | $2,284 | $134 |
| Injection beneath lining of large bowel using a flexible endoscope | 17 | $459 | $27 |
2014: 9 services
| Biopsy of large bowel using a flexible endoscope | 118 | $18,760 | $158 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 51 | $13,757 | $265 |
| Short return visit (20+ min) | 96 | $7,786 | $62 |
| New patient visit (45+ min) | 39 | $5,675 | $146 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 60 | $5,472 | $88 |
| Return visit (30+ min) | 25 | $2,557 | $88 |
| New patient visit (30+ min) | 13 | $991 | $76 |
| Short return visit | 11 | $486 | $37 |
| Injection beneath lining of large bowel using a flexible endoscope | 11 | $315 | $26 |
2013: 10 services
| Biopsy of large bowel using a flexible endoscope | 65 | $10,043 | $152 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 36 | $9,338 | $252 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 56 | $7,483 | $125 |
| Short return visit (20+ min) | 81 | $7,429 | $66 |
| New patient visit (45+ min) | 27 | $3,722 | $138 |
| Biopsy of lower large bowel using a flexible endoscope | 11 | $1,918 | $160 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 15 | $1,307 | $87 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 16 | $1,076 | $34 |
| New patient visit (30+ min) | 11 | $909 | $83 |
| Short return visit | 17 | $630 | $37 |
Drugs they prescribed that Part D paid
$426,164
Pharmacies billed $426,164 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 760) in 2024. At or below the middle of the specialty; the typical gastroenterology clinician is at 0%.
575 generic and 185 brand-name prescriptions · $426,164 in drug cost · 21 antibiotic prescriptions to 15 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Linzess | 56 | $53,956 | $963 |
| Creon | 11 | $28,533 | $2,594 |
| Motegrity | 27 | $27,299 | $1,011 |
| Dexlansoprazole Dr | 36 | $11,773 | $327 |
| Sod Sulf-Potass Sulf-Mag Sulf | 95 | $5,909 | $62 |
See all 15 drugs
| Linzess | 56 | $53,956 | $963 |
| Creon | 11 | $28,533 | $2,594 |
| Motegrity | 27 | $27,299 | $1,011 |
| Dexlansoprazole Dr | 36 | $11,773 | $327 |
| Sod Sulf-Potass Sulf-Mag Sulf | 95 | $5,909 | $62 |
| Cholestyramine | 30 | $3,129 | $104 |
| Pantoprazole | 109 | $1,839 | $17 |
| Famotidine | 106 | $1,796 | $17 |
| Esomeprazole Magnesium | 18 | $1,512 | $84 |
| Lansoprazole | 12 | $1,140 | $95 |
| Omeprazole | 42 | $619 | $15 |
| Amitriptyline | 22 | $215 | $10 |
| Ondansetron Odt | 15 | $112 | $7 |
| Baclofen | 17 | $76 | $4 |
| Ondansetron | 16 | $40 | $2 |
Year by year
| 2024 | 760 | 228 | 0% (0) | 24% | $426,164 |
| 2023 | 607 | 187 | 0% (0) | None | $735,394 |
| 2022 | 596 | 190 | None | 35% | $224,441 |
| 2021 | 578 | 212 | None | 47% | $185,786 |
| 2020 | 503 | 142 | 0% (0) | None | $157,631 |
| 2019 | 404 | 151 | 0% (0) | 35% | $90,721 |
| 2018 | 643 | 203 | None | 37% | $200,123 |
| 2017 | 676 | 220 | 0% (0) | None | $201,697 |
| 2016 | 722 | 253 | None | None | $164,035 |
| 2015 | 608 | 233 | None | 41% | $437,125 |
| 2014 | 570 | 196 | None | None | $201,870 |
| 2013 | 362 | 146 | 0% (0) | None | $62,700 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 13 drugs
| Stelara | 20 | $563,504 | $28,175 |
| Linzess | 54 | $41,430 | $767 |
| Motegrity | 25 | $22,535 | $901 |
| Dexlansoprazole Dr | 24 | $10,665 | $444 |
| Sutab | 23 | $3,839 | $167 |
| Sod Sulf-Potass Sulf-Mag Sulf | 39 | $3,158 | $81 |
| Lubiprostone | 12 | $1,574 | $131 |
| Pantoprazole | 94 | $1,486 | $16 |
| Suprep | 11 | $1,320 | $120 |
| Famotidine | 55 | $1,317 | $24 |
| Omeprazole | 68 | $764 | $11 |
| Amitriptyline | 21 | $355 | $17 |
| Hydrocortisone | 14 | $280 | $20 |
2022: 14 drugs
| Creon | 12 | $32,690 | $2,724 |
| Linzess | 36 | $30,459 | $846 |
| Motegrity | 27 | $14,035 | $520 |
| Clenpiq | 41 | $7,280 | $178 |
| Dexlansoprazole Dr | 13 | $7,258 | $558 |
| Suprep | 31 | $3,596 | $116 |
| Cholestyramine | 24 | $2,754 | $115 |
| Sucralfate | 18 | $1,698 | $94 |
| Pantoprazole | 67 | $1,408 | $21 |
| Famotidine | 68 | $1,353 | $20 |
| Omeprazole | 68 | $626 | $9 |
| Amitriptyline | 24 | $253 | $11 |
| Ondansetron | 12 | $189 | $16 |
| Dicyclomine | 13 | $120 | $9 |
2021: 12 drugs
| Linzess | 66 | $50,959 | $772 |
| Xifaxan | 13 | $26,627 | $2,048 |
| Motegrity | 32 | $18,176 | $568 |
| Dexilant | 23 | $12,429 | $540 |
| Mesalamine | 11 | $9,694 | $881 |
| Suprep | 79 | $8,746 | $111 |
| Clenpiq | 41 | $6,573 | $160 |
| Cholestyramine | 33 | $4,828 | $146 |
| Pantoprazole | 50 | $1,050 | $21 |
| Famotidine | 35 | $1,032 | $29 |
| Omeprazole | 38 | $289 | $8 |
| Amitriptyline | 29 | $288 | $10 |
2020: 10 drugs
| Motegrity | 39 | $22,875 | $587 |
| Linzess | 36 | $22,023 | $612 |
| Dexilant | 24 | $11,091 | $462 |
| Suprep | 61 | $6,341 | $104 |
| Cholestyramine | 36 | $4,122 | $115 |
| Famotidine | 57 | $1,001 | $18 |
| Pantoprazole | 37 | $848 | $23 |
| Omeprazole | 31 | $450 | $15 |
| Amitriptyline | 31 | $372 | $12 |
| Rabeprazole | 11 | $310 | $28 |
2019: 11 drugs
| Creon | 11 | $30,696 | $2,791 |
| Mesalamine | 12 | $16,440 | $1,370 |
| Suprep | 67 | $6,673 | $100 |
| Dexilant | 17 | $4,756 | $280 |
| Cholestyramine | 19 | $2,719 | $143 |
| Omeprazole | 37 | $693 | $19 |
| Esomeprazole Magnesium | 11 | $551 | $50 |
| Pantoprazole | 25 | $414 | $17 |
| Amitriptyline | 26 | $301 | $12 |
| Ranitidine | 31 | $264 | $9 |
| Famotidine | 14 | $180 | $13 |
2018: 12 drugs
| Xifaxan | 24 | $66,379 | $2,766 |
| Linzess | 41 | $20,391 | $497 |
| Dexilant | 29 | $13,624 | $470 |
| Amitiza | 22 | $8,111 | $369 |
| Entecavir | 18 | $4,478 | $249 |
| Pantoprazole | 89 | $1,312 | $15 |
| Suprep | 11 | $1,046 | $95 |
| Ranitidine | 84 | $1,001 | $12 |
| Peg 3350-Electrolyte | 61 | $976 | $16 |
| Gavilyte-N | 26 | $421 | $16 |
| Omeprazole | 21 | $374 | $18 |
| Dicyclomine | 13 | $146 | $11 |
2017: 16 drugs
| Humira | 11 | $49,467 | $4,497 |
| Xifaxan | 16 | $28,441 | $1,778 |
| Budesonide Ec | 19 | $20,176 | $1,062 |
| Entecavir | 13 | $16,923 | $1,302 |
| Linzess | 38 | $16,433 | $432 |
| Dexilant | 61 | $16,202 | $266 |
| Apriso | 23 | $8,773 | $381 |
| Cholestyramine | 20 | $2,201 | $110 |
| Esomeprazole Magnesium | 11 | $1,818 | $165 |
| Peg 3350-Electrolyte | 78 | $1,151 | $15 |
| Omeprazole | 52 | $1,056 | $20 |
| Pantoprazole | 52 | $839 | $16 |
| Ranitidine | 62 | $561 | $9 |
| Gavilyte-N | 22 | $373 | $17 |
| Dicyclomine | 13 | $105 | $8 |
| Spironolactone | 13 | $90 | $7 |
2016: 17 drugs
| Humira | 13 | $51,458 | $3,958 |
| Linzess | 44 | $16,145 | $367 |
| Budesonide Ec | 18 | $8,124 | $451 |
| Apriso | 23 | $6,374 | $277 |
| Dexilant | 24 | $5,731 | $239 |
| Delzicol | 12 | $3,534 | $294 |
| Cholestyramine | 16 | $1,964 | $123 |
| Peg 3350-Electrolyte | 89 | $1,358 | $15 |
| Pantoprazole | 48 | $941 | $20 |
| Rabeprazole | 12 | $940 | $78 |
| Omeprazole | 61 | $814 | $13 |
| Gavilyte-N | 45 | $803 | $18 |
| Azathioprine | 16 | $484 | $30 |
| Ranitidine | 43 | $370 | $9 |
| Peg 3350-Electrolyte | 11 | $103 | $9 |
| Prednisone | 17 | $62 | $4 |
| Lorazepam | 15 | $59 | $4 |
2015: 15 drugs
| Entecavir | 15 | $18,635 | $1,242 |
| Budesonide Ec | 11 | $8,626 | $784 |
| Linzess | 21 | $6,216 | $296 |
| Dexilant | 23 | $6,200 | $270 |
| Cholestyramine | 11 | $1,808 | $164 |
| Peg 3350-Electrolyte | 82 | $1,441 | $18 |
| Pantoprazole | 69 | $1,084 | $16 |
| Moviprep | 13 | $1,049 | $81 |
| Sulfasalazine | 14 | $925 | $66 |
| Gavilyte-N | 45 | $887 | $20 |
| Omeprazole | 56 | $686 | $12 |
| Azathioprine | 15 | $511 | $34 |
| Ondansetron | 15 | $276 | $18 |
| Ranitidine | 28 | $212 | $8 |
| Lorazepam | 16 | $68 | $4 |
2014: 17 drugs
| Baraclude | 14 | $22,748 | $1,625 |
| Budesonide Ec | 14 | $11,716 | $837 |
| Nexium | 19 | $6,379 | $336 |
| Dexilant | 28 | $6,344 | $227 |
| Linzess | 13 | $4,127 | $317 |
| Cholestyramine | 13 | $1,430 | $110 |
| Rabeprazole | 11 | $1,203 | $109 |
| Peg-3350 | 61 | $1,096 | $18 |
| Pantoprazole | 46 | $977 | $21 |
| Sulfasalazine | 11 | $883 | $80 |
| Omeprazole | 38 | $773 | $20 |
| Sulfazine | 11 | $608 | $55 |
| Azathioprine | 13 | $465 | $36 |
| Gavilyte-N | 25 | $435 | $17 |
| Ranitidine | 35 | $387 | $11 |
| Ondansetron | 15 | $287 | $19 |
| Trilyte With Flavor Packets | 12 | $231 | $19 |
2013: 11 drugs
| Baraclude | 16 | $23,878 | $1,492 |
| Nexium | 20 | $6,353 | $318 |
| Omeprazole | 48 | $1,659 | $35 |
| Moviprep | 15 | $1,058 | $71 |
| Peg-3350 With Flavor Packs | 42 | $778 | $19 |
| Sulfasalazine | 13 | $673 | $52 |
| Azathioprine | 17 | $645 | $38 |
| Pantoprazole | 21 | $443 | $21 |
| Gavilyte-N | 21 | $392 | $19 |
| Ranitidine | 23 | $252 | $11 |
| Baclofen | 11 | $91 | $8 |
Money from drug and device companies
$66 in 2025
| 2025 | 2 | 2 | None | $66 |
| 2023 | 1 | 1 | None | $14 |
| 2021 | 1 | 1 | None | $14 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Braintree Laboratories | Suflave | $35 | 1 payment
|
| Pfizer | Velsipity | $31 | 1 payment
|
See all 2 published payments
| Braintree Laboratories | Meals · 2025-08-28 | Suflave | $35 |
| Pfizer | Education · 2025-04-14 | Velsipity | $31 |
See earlier years (2023, 2021)
2023: $14
| Abbvie | Linzess | $14 | 1 payment
|
2021: $14
| Celgene | Zeposia | $14 | 1 payment
|
Professional record
- NPI
- 1376657734
- Licence
- CA A69657California A69657: Current · expires 2026-11-30
- Trained
- University of Southern California Keck School of Medicine, 1998
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207RG0100X (207RG0100X)
- Mailing address
- 321 Middlefield Rd Ste 260, Menlo Park, CA, 94025
- NPI first listed
- 2006-08-19
- NPI last updated
- 2024-04-15
- NPI record certified
- 2024-04-15
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 795 El Camino Real, Palo Alto, CA, 94301